ZYME vs CELC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 23, 2026

ZYME

52.2
AI Score
VS
ZYME Wins

CELC

48.7
AI Score

Investment Advisor Scores

ZYME

52score
Recommendation
HOLD

CELC

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME CELC Winner
Net Income -81.13M -131.71M ZYME
Operating Income -92.55M -116.63M ZYME
ROE -30.2% 1030.5% CELC
ROA -23.4% -15.9% CELC
Total Assets 346.53M 828.22M CELC
Cash 41.16M 182.05M CELC
Current Ratio 5.88 8.93 CELC
Free Cash Flow -34.53M -110.79M ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: -19.0% · 3M: -0.7% CELC 1M: -25.1% · 3M: -33.6%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 40

RSI (14): 40.2 · Price: $25.15

CELC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 31

RSI (14): 30.6 · Price: $72.10

Fundamentals Snapshot

Metric ZYME CELC
Market Cap — —
Forward P/E 28.9 -901.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 0.0%
Gross Margin -2.5% —
Operating Margin -9.2% 0.0%
EPS -2.02 -4.06
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.